{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T17:54:41Z","timestamp":1776448481378,"version":"3.51.2"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,6,9]],"date-time":"2018-06-09T00:00:00Z","timestamp":1528502400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s10157-018-1597-8","type":"journal-article","created":{"date-parts":[[2018,6,9]],"date-time":"2018-06-09T05:03:00Z","timestamp":1528520580000},"page":"1371-1378","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The first year results of mizoribine\/tacrolimus-based multitarget treatment for consecutive patients with lupus nephritis"],"prefix":"10.1007","volume":"22","author":[{"given":"Hidetoshi","family":"Kagawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsutomu","family":"Hiromasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryutaro","family":"Yamanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reika","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Tsunashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuyuki","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken-ei","family":"Sada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,9]]},"reference":[{"key":"1597_CR1","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/nrrheum.2015.174","volume":"12","author":"CC Mok","year":"2016","unstructured":"Mok CC. Towards new avenues in the management of lupus glomerulonephritis. Nat Rev Rheumatol. 2016;12:221\u201334.","journal-title":"Nat Rev Rheumatol"},{"key":"1597_CR2","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/acr.21664","volume":"64","author":"BH Hahn","year":"2012","unstructured":"Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res. 2012;64:797\u2013808.","journal-title":"Arthritis Care Res"},{"key":"1597_CR3","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1681\/ASN.2008101028","volume":"20","author":"GB Appel","year":"2009","unstructured":"Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009;20:1103\u201312.","journal-title":"J Am Soc Nephrol"},{"key":"1597_CR4","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1136\/annrheumdis-2014-206897","volume":"75","author":"F Tamirou","year":"2016","unstructured":"Tamirou F, D\u2019Cruz D, Sangle S, Remy P, Vasconcelos C, Fiehn C, et al. Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis. Ann Rheum Dis. 2016;75:526\u201331.","journal-title":"Ann Rheum Dis"},{"key":"1597_CR5","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3899\/jrheum.080625","volume":"36","author":"MM Ward","year":"2009","unstructured":"Ward MM. Changes in the incidence of endstage renal disease due to lupus nephritis in the United States, 1996\u20132004. J Rheumatol. 2009;36:63\u20137.","journal-title":"J Rheumatol"},{"key":"1597_CR6","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1093\/rheumatology\/ker101","volume":"50","author":"SC Croca","year":"2011","unstructured":"Croca SC, Rodrigues T, Isenberg DA. Assessment of a lupus nephritis cohort over a 30-year period. Rheumatology. 2011;50:1424\u201330.","journal-title":"Rheumatology"},{"key":"1597_CR7","doi-asserted-by":"publisher","first-page":"18","DOI":"10.7326\/M14-1030","volume":"162","author":"Z Liu","year":"2015","unstructured":"Liu Z, Zhang H, Liu Z, Xing C, Fu P, Ni Z, et al. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Intern Med. 2015;162:18\u201326.","journal-title":"Ann Intern Med"},{"key":"1597_CR8","doi-asserted-by":"publisher","first-page":"618","DOI":"10.3109\/14397595.2013.844397","volume":"24","author":"H Ikeuchi","year":"2014","unstructured":"Ikeuchi H, Hiromura K, Takahashi S, Mishima K, Sakurai N, Sakairi T, et al. Efficacy and safety of multi-target therapy using a combination of tacrolimus, mycophenolate mofetil and a steroid in patients with active lupus nephritis. Mod Rheumatol. 2014;24:618\u201325.","journal-title":"Mod Rheumatol"},{"key":"1597_CR9","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1590\/S1413-86702006000200011","volume":"10","author":"AT Song","year":"2006","unstructured":"Song AT, Abdala E, Bonazzi PR, Bacchella T, Machado MC. Does mycophenolate mofetil increase the risk of cytomegalovirus infection in solid organ transplant recipients? A mini-review. Braz J Infect Dis. 2006;10:132\u20138.","journal-title":"Braz J Infect Dis"},{"key":"1597_CR10","first-page":"1567","volume":"31","author":"M Fernandez Nieto","year":"2016","unstructured":"Fernandez Nieto M, Jayne DR. Con. The use of calcineurin inhibitors in the treatment of lupus nephritis. NDT. 2016;31:1567\u201371.","journal-title":"NDT"},{"key":"1597_CR11","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.transproceed.2015.12.117","volume":"48","author":"H Ushigome","year":"2016","unstructured":"Ushigome H, Uchida K, Nishimura K, Akioka K, Fukuda Y, Yuzawa K, et al. Efficacy and safety of high-dose mizoribine combined with cyclosporine, basiliximab, and corticosteroids in renal transplantation: a Japanese multicenter study. Transplant Proc. 2016;48:794\u20138.","journal-title":"Transplant Proc"},{"key":"1597_CR12","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1007\/s10157-012-0632-4","volume":"16","author":"H Kagawa","year":"2012","unstructured":"Kagawa H, Hiromasa T, Hara T, Takaki A, Yamanaka R, Sada KE, et al. Mizoribine, tacrolimus, and corticosteroid combination therapy successfully induces remission in patients with lupus nephritis. Clin Exp Nephrol. 2012;16:760\u20136.","journal-title":"Clin Exp Nephrol"},{"key":"1597_CR13","first-page":"288","volume":"29","author":"DD Gladmann","year":"2002","unstructured":"Gladmann DD, Ibanez D, Urowitz MZ. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29:288\u201391.","journal-title":"J Rheumatol"},{"key":"1597_CR14","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s10067-013-2383-3","volume":"33","author":"Y Fei","year":"2014","unstructured":"Fei Y, Shi X, Gan F, Li X, Zhang W, Li M, et al. Death causes and pathogens analysis of systemic lupus erythematosus during the past 26 years. Clin Rheumatol. 2014;33:57\u201363.","journal-title":"Clin Rheumatol"},{"key":"1597_CR15","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1034\/j.1399-0012.2000.140206.x","volume":"14","author":"JM Samiento","year":"2000","unstructured":"Samiento JM, Dockrell DH, Schwab TR, Munn SR, Paya CV. Mycophenolate mofetil increases cytomegalovirus invasive organ disease in renal transplant patients. Clin Transplant. 2000;14:136\u20138.","journal-title":"Clin Transplant"},{"key":"1597_CR16","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s10157-012-0669-4","volume":"17","author":"N Yoshimura","year":"2013","unstructured":"Yoshimura N, Ushigome H, Akioka K, Nobori S, Suzuki T, Sakai K, et al. The beneficial effect of high-dose mizoribine combined with cyclosporine, basiliximab, and corticosteroids on CMV infection in renal transplant recipients. Clin Exp Nephrol. 2013;17:127\u201333.","journal-title":"Clin Exp Nephrol"},{"key":"1597_CR17","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1124\/jpet.109.160630","volume":"333","author":"T Kuramoto","year":"2010","unstructured":"Kuramoto T, Daikoku T, Yoshida Y, Takemoto M, Oshima K, Eizuru Y, et al. Novel anticytomegalovirus activity of immunosuppressant mizoribine and its synergism with ganciclovir. J Pharmacol Exp Ther. 2010;333:816\u201321.","journal-title":"J Pharmacol Exp Ther"},{"key":"1597_CR18","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1080\/14397595.2017.1349573","volume":"28","author":"T Takeuchi","year":"2018","unstructured":"Takeuchi T, Okada K, Yoshida H, Yagi N. Post-marketing surveillance study of the long-term use of mizoribine for the treatment of lupus nephritis: 2-year results. Mod Rheumatol. 2018;28:85\u201391.","journal-title":"Mod Rheumatol."},{"key":"1597_CR19","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1177\/095632029400500603","volume":"5","author":"Y Kosugi","year":"1994","unstructured":"Kosugi Y, Saito Y, Mori S, Watanabe J, Baba M, Shigeta S. Antiviral activities of mizoribine and other inosine monophosphate dehydrogenase inhibitors against several ortho- and paramyxoviruses. Antiviral Chem Chemother. 1994;5:366\u201371.","journal-title":"Antiviral Chem Chemother"},{"key":"1597_CR20","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.bbrc.2005.03.062","volume":"330","author":"K Naka","year":"2005","unstructured":"Naka K, Ikeda M, Abe KI, Dansako H, Kato N. Mizoribine inhibits hepatitis C virus RNA replication: effect of combination with interferon-alpha. Biochem Biophys Res Commun. 2005;330:871\u20139.","journal-title":"Biochem Biophys Res Commun"},{"key":"1597_CR21","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1006\/bbrc.2000.3104","volume":"274","author":"S Takahashi","year":"2000","unstructured":"Takahashi S, Wakui H, Gustafsson JA, Zilliacus J, Itoh H. Functional interaction of the immunosuppressant mizoribine with the 14-3-3 protein. Biochem Biophys Res Commun. 2000;274:87\u201392.","journal-title":"Biochem Biophys Res Commun"},{"key":"1597_CR22","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1159\/000314668","volume":"116","author":"S Takeuchi","year":"2010","unstructured":"Takeuchi S, Hiromura K, Tomioka M, Takahashi S, Sakairi T, Maeshima A, et al. The immunosuppressive drug mizoribine directly prevents podocyte injury in puromycin aminonucleoside nephrosis. Nephron Exp Nephrol. 2010;116:e3\u2013e10.","journal-title":"Nephron Exp Nephrol"},{"key":"1597_CR23","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1046\/j.1365-2249.2000.01242.x","volume":"120","author":"S Hirohata","year":"2000","unstructured":"Hirohata S, Nakanishi K, Yanagida T. Inhibition of cyclin A gene expression in human B cells by an immunosuppressant mizoribine. Clin Exp Immunol. 2000;120:448\u201353.","journal-title":"Clin Exp Immunol"},{"key":"1597_CR24","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1203\/PDR.0b013e3181b9b48a","volume":"66","author":"S Hara","year":"2009","unstructured":"Hara S, Umino D, Someya T, Fujinaga S, Ohtomo Y, Murakami H, et al. Protective effects of mizoribine on cyclosporine A nephropathy in rats. Pediatr Res. 2009;66:524\u20137.","journal-title":"Pediatr Res"},{"key":"1597_CR25","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3109\/s10165-007-0567-x","volume":"17","author":"T Kuroda","year":"2007","unstructured":"Kuroda T, Hirose S, Tanabe N, Sato H, Nakatsue T, Ajiro J, et al. Mizoribine therapy for patients with lupus nephritis: the association between peak mizoribine concentration and clinical efficacy. Mod Rheumatol. 2007;17:206\u201312.","journal-title":"Mod Rheumatol"},{"key":"1597_CR26","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1007\/s00467-006-0120-8","volume":"21","author":"H Tanaka","year":"2006","unstructured":"Tanaka H, Tsugawa K, Suzuki K, Nakahata T, Ito E. Long-term mizoribine intermittent pulse therapy for young patients with flare of lupus nephritis. Pediatr Nephrol. 2006;21:962\u20136.","journal-title":"Pediatr Nephrol"},{"key":"1597_CR27","doi-asserted-by":"publisher","first-page":"390","DOI":"10.5414\/CNP60390","volume":"60","author":"H Tanaka","year":"2003","unstructured":"Tanaka H, Suzuki K, Nakahata T, Tsugawa K, Ito E, Waga S. Mizoribine oral pulse therapy for patients with disease flare of lupus nephritis. Clin Nephrol. 2003;60:390\u20134.","journal-title":"Clin Nephrol"},{"key":"1597_CR28","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3109\/s10165-012-0645-6","volume":"23","author":"E Nishi","year":"2012","unstructured":"Nishi E, Kameda H, Ogawa H, Nagasawa H, Takei H, Okuyama A, et al. Efficacy of weekly mizoribine pulse therapy in refractory lupus nephritis. Mod Rheumatol. 2012;23:97\u2013103.","journal-title":"Mod Rheumatol"},{"key":"1597_CR29","first-page":"705","volume":"47","author":"W Yumura","year":"1999","unstructured":"Yumura W, Uchida K, Kawashima A, Kobayashi H, Miwa N. Evaluation of plasma concentration of mizoribine as an immunosuppressive agent in lupus nephritis patients. Kidney Dialysis. 1999;47:705\u20138 (in Japanese).","journal-title":"Kidney Dialysis"},{"key":"1597_CR30","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1093\/rheumatology\/ker410","volume":"51","author":"G Ruiz-Irastorza","year":"2012","unstructured":"Ruiz-Irastorza G, Danza A, Khamashta M. Glucocorticoid use and abuse in SLE. Rheumatology. 2012;51:1145\u201353.","journal-title":"Rheumatology"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10157-018-1597-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-018-1597-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-018-1597-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,8]],"date-time":"2019-06-08T23:20:56Z","timestamp":1560036056000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10157-018-1597-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,9]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1597"],"URL":"https:\/\/doi.org\/10.1007\/s10157-018-1597-8","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,9]]},"assertion":[{"value":"12 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All procedures performed in the present study were in accordance with the ethical standards of the institutional review boards of Japanese Red Cross Himeji Hospital (IRB approval number 2016-18) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare that no conflicts of interest exist.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}